<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974075</url>
  </required_header>
  <id_info>
    <org_study_id>1460/2016</org_study_id>
    <nct_id>NCT02974075</nct_id>
  </id_info>
  <brief_title>Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy</brief_title>
  <official_title>Safety and Efficacy of Salvage Lymph Node Dissection in Prostate Cancer Patients With Nodal Recurrence After Radical Prostatectomy With Curative Intent - a Prospective Single Center Phase I/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Despite continuous technical improvements in urologic surgery, up to 40% of prostate cancer&#xD;
      patients will develop biochemical recurrence after radical prostatectomy (RP), potentially&#xD;
      because of micro metastasis at the time of the primary surgery.&#xD;
&#xD;
      With improved radiological modalities and nuclear medicine tracers like 68Ga-PSMA PET/CT,&#xD;
      which allow the localization of the site of recurrence, there is increasing interest in&#xD;
      metastasis directed therapies, such as salvage lymph node dissection.&#xD;
&#xD;
      The pelvic extended salvage lymph node dissection (sLND) is a promising option for treating&#xD;
      prostate cancer patients with local recurrence after radical prostatectomy with curative&#xD;
      intent. Several retrospective series has been published to determine the local value of sLND.&#xD;
      Despite the first data seem to be feasible and promising, to date no prospective evaluation&#xD;
      has been made. Thus sLND is still experimental according to the guidelines and is considered&#xD;
      as an off label therapy.&#xD;
&#xD;
      This prospective single center phase I/II study was conducted to investigate the safety and&#xD;
      early efficacy of salvage lymph node dissection in prostate cancer patients with local pelvic&#xD;
      recurrence after radical prostatectomy (RP) with curative intention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of periperative complications within 90 days after surgery</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Prostate specific antigen value after 6 weeks.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate Specific Antigen doubling time</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until development of castration resistance</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until development of distant metastasis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Salvage lymph node dissection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo extended pelvic salvage lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salvage lymph node dissection</intervention_name>
    <description>Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder</description>
    <arm_group_label>Salvage lymph node dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer patients with lymph node metastasis in pelvic imaging&#xD;
&#xD;
          -  Status post radical prostatectomy with curative intent&#xD;
&#xD;
          -  Ability for informed consent&#xD;
&#xD;
          -  No sign for bone or visceral metastasis&#xD;
&#xD;
          -  Male &gt; 18 years&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male &lt; 18 years&#xD;
&#xD;
          -  No ability for informed consent&#xD;
&#xD;
          -  Sign for bone or visceral metastasis&#xD;
&#xD;
          -  Deep venous thrombosis or pulmonary embolism within the last 6 months before study&#xD;
             screening&#xD;
&#xD;
          -  ECOG performance status 2 or more&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahrokh Francois Shariat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernhard Grubmüller, MD</last_name>
    <phone>004314040026150</phone>
    <email>bernhard.grubmueller@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Grubmüller, MD</last_name>
      <phone>004314040026150</phone>
      <email>bernhard.grubmueller@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Bernhard Grubmüller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

